Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2026)

Axsome Therapeutics has disclosed Change in Receivables across 5 years of filings, most recently posting $26.6 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $26.6 million, up 37.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.7 million (up 49.54% YoY), and the FY2025 annual result was $82.5 million, up 74.78% from the prior year.
• Change in Receivables came in at $26.6 million for Q1 2026 at Axsome Therapeutics, down from $28.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $37.4 million in Q2 2025 to a low of -$2.3 million in Q3 2025.
• The 5-year median for Change in Receivables is $17.4 million (2022), against an average of $15.7 million.
• Peak annual rise in Change in Receivables reached 193.21% in 2025, while the deepest fall reached 161.75% in 2025.
• Axsome Therapeutics' Change in Receivables stood at $17.4 million in 2022, then dropped by 5.7% to $16.4 million in 2023, then gained by 9.14% to $17.9 million in 2024, then jumped by 56.14% to $28.0 million in 2025, then dropped by 4.86% to $26.6 million in 2026.
• The last three Change in Receivables figures came in at $26.6 million (Q1 2026), $28.0 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.